Late breaking at #ACR23: extension of this study for dazodalibep (anti-CD40L) for Sjogren’s symptoms Another six months with a crossover - & sustained symptomatic benefit after cessation. Fascinating, addresses a desperate clinical need, bring on the phase 3! ABSTL10 @RheumNow https://t.co/zUfnGEZefj https://t.co/S3lLwhwl85